Research To Practice | Oncology Videos

Latest Episodes:

ER-Positive Breast Cancer | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer Jan 04, 2023

Show notes

Featuring perspectives from Drs Aditya Bardia, Matthew Goetz, Virginia Kaklamani, Kevin Kalinsky and Hope Rugo, including the following topics:

Current Role of Genomic Assays for Hormone Receptor (HR)-Positive Localized Breast Cancer
- Introduction (0:00)
- Case: A premenopausal woman in her early 40s with 9-mm, Grade III, ER/PR-positive, HER2-negative, node-negative infiltrating ductal carcinoma (IDC) – 21-gene Recurrence Score® 22 — Alan B Astrow, MD (3:39)
- Case: A premenopausal woman in her mid 30s with 3.6-cm, ER/PR-positive, HER2-low (IHC 1+), sentinel node-positive (4/4) multifocal IDC after bilateral mastectomies, adjuvant AC-T and ovarian function suppression (OFS)/aromatase inhibitor, Ki67 50% — Laila Agrawal, MD (9:40)
- Dr Goetz presentation (19:43)
Optimizing the Management of Localized ER-Positive Breast Cancer
- Case: A woman in her early 40s with 5.5-cm, ER/PR-positive, HER2-negative, node-positive (20/21) IDC after bilateral mastectomies, bilateral salpingo-oophorectomy, adjuvant AC-T and initiation of letrozole/abemaciclib, Ki-67 3% — Susmitha Apuri, MD (32:22)
- Case: A woman in her mid 50s with de novo ER-positive, PR-negative, HER2-negative ulcerated breast cancer with pulmonary and extensive spinal metastases — Jennifer L Dallas, MD (40:45)
- Dr Kaklamani presentation (45:32)
Selection and Sequencing of Therapy for Patients with ER-Positive Metastatic Breast Cancer (mBC)
- Case: A woman in her early 50s with ER/PR-positive, HER2-low mBC with a PI3KCA mutation who experiences a dramatic response to rechallenge with fulvestrant and a CDK4/6i (abemaciclib); now with progression and cytopenias — Kapisthalam (KS) Kumar, MD (59:07)
- Dr Kalinsky presentation (1:09:53)
Recent Appreciation of HER2 Low as a Unique Subset of HR-Positive Breast Cancer
- Case: A premenopausal woman in her late 30s with ER/PR-positive, HER2-low (IHC 1+) IDC after adjuvant tamoxifen and OFS x 5 years, now with bone and liver metastases — Dr Agrawal (1:19:45)
- Dr Bardia presentation (1:24:29)
Novel Strategies Under Investigation for Patients with HR-Positive mBC
- Case: A woman in her early 90s with ER/PR-positive, HER2-low (IHC 1+) mBC and progressive disease on multiple lines of endocrine and chemotherapy receives T-DXd — Dr Astrow (1:38:44)
- Case: A woman in her mid 40s with ER/PR-positive, HER2-low (IHC 2+) mBC who has received fulvestrant/abemaciclib, now receiving exemestane/everolimus – ESR1 and PIK3CA mutations — Dr Dallas (1:44:15)
- Dr Rugo presentation (1:49:58)

CME information and select publications

Chronic Lymphocytic Leukemia | Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia — What Clinicians Want to Know Dec 28, 2022

Show notes

Featuring perspectives from Drs Alexey Danilov, Matthew Davids, Lindsey Roeker, Philip Thompson and Prof Dr Arnon Kater, including the following topics:

Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
- Introduction (0:00)
- Cases: A man in his early 90s with Rai Stage 0 CLL who underwent surveillance x 5 years and now develops cytopenias and transfusion-dependent anemia, and a woman in her late 60s with IGHV-unmutated CLL who develops night sweats, rapid doubling time of ALC — Bhavana (Tina) Bhatnagar, DO and Jennifer L Dallas, MD (3:18)
- Case: A man in his mid 50s with relapsed CLL after ibrutinib x 5 years now with disease progression — Amany R Keruakous, MD, MS (9:11)
- Dr Danilov presentation (16:47)
Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors for CLL
- Case: A man in his late 70s with IGHV-unmutated CLL under observation for many years who develops B symptoms, cytopenias and lymphadenopathy — Henna Malik, MD (32:15)
- Prof Kater presentation (37:18)
Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations
- Case: A man in his early 70s with multiple musculoskeletal comorbidities and transportation limitations develops symptomatic IGHV-mutated CLL with cytopenias — Syed F Zafar, MD (51:08)
- Cases: A man in his mid 50s with del(17p) CLL and significant lymphadenopathy and B symptoms who receives acalabrutinib and a woman in her early 70s with IGHV-mutated CLL and a complex karyotype — Dr Keruakous and Spencer H Bachow, MD (55:10)
- Dr Davids presentation (1:03:01)
Selection and Sequencing of Available Therapies for Relapsed/Refractory Disease
- Case: A man in his mid 70s with relapsed del(17p) CLL after ibrutinib with multiple chronic low-grade toxicities — Dr Bhatnagar (1:16:23)
- Dr Thompson presentation (1:20:56)
Promising Investigational Agents and Strategies
- Case: A woman in her late 70s with CLL (p53, 11q, 13q mutations), disease progression on ibrutinib and a BTK C481S mutation detected on repeat testing — Dr Bachow (1:39:09)
- Case: A man in his late 70s who develops Richter's transformation while receiving obinutuzumab/venetoclax for CLL — Justin Peter Favaro, MD, PhD (1:43:12)
- Dr Roeker presentation (1:48:29)

CME information and select publications

HER2-Positive Breast Cancer | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast Cancer Dec 22, 2022

Show notes

Featuring perspectives from Drs Erika Hamilton, Sara Hurvitz, Ian Krop, Shanu Modi and Sara Tolaney, including the following topics:

Optimizing the Management of Localized HER2-Positive Breast Cancer
- Introduction (0:00)
- Case: A woman in her mid 60s with pulmonary hypertension and triple-positive, node-positive infiltrating ductal carcinoma (IDC) after neoadjuvant TCHP and clinical complete remission — Susmitha Apuri, MD (4:31)
- Case: A woman in her early 60s with a 1.7-cm, triple-positive, clinically node-negative IDC — Ranju Gupta, MD (10:05)
- Dr Tolaney presentation (18:44)
Current Considerations in the Treatment of HER2-Positive Metastatic Breast Cancer (mBC)
- Case: A woman in her early 60s with an 8-cm, ER-negative, PR-positive, HER2-positive IDC and positive nodes bilaterally after neoadjuvant TCHP and bilateral mastectomies with no residual disease — Henna Malik, MD (31:12)
- Case: A woman in her late 50s with Stage IIIA, ER/PR-negative, HER2-positive, node-positive IDC with residual disease after neoadjuvant TCHP and mastectomy — Laila Agrawal, MD ()35:29
- Dr Krop presentation (42:56)
Management of HER2-Positive Breast Cancer with CNS Metastases
- Case: A woman in her early 90s with "mild" dementia and ER/PR-negative, HER2 IHC 1+ IDC with symptomatic chest wall recurrence after neoadjuvant paclitaxel/trastuzumab and lumpectomy — Alan B Astrow, MD (54:54)
- Case: A woman in her late 40s with a triple-positive multifocal IDC with a gBRCA2 mutation and HER2-negative axillary nodes after neoadjuvant TCHP and bilateral mastectomies with significant response in the breast but 49 positive nodes — Zanetta S Lamar, MD (1:00:01)
- Dr Hamilton presentation (1:06:51)
Recent Appreciation of HER2 Low as a Unique Disease Subset; Future Directions in the Management of HER2-Positive and HER2-Low Breast Cancer
- Cases: A premenopausal woman in her late 30s with a triple-positive IDC who develops brain metastases while receiving THP; A woman in her late 60s with an ER/PR-negative, HER2-positive IDC who develops brain metastases after first-line THP and second-line T-DM1 — Kelly Yap, MD & Rohit Gosain, MD (1:20:46)
- Case: A woman in her mid 60s with ER/PR-negative, HER2-positive mBC treated with paclitaxel/trastuzumab, then T-DXd on progression — Joanna Metzner-Sadurski, MD (1:29:40)
- Dr Modi presentation (1:40:51)
Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy
- Case: A woman in her early 60s with recurrent triple-positive mBC whose disease converts to HER2-negative, PIK3CA-positive at the time of progression — Dhatri Kodali, MD (2:01:10)
- Dr Hurvitz presentation (2:05:08)

CME information and select publications

Ovarian Cancer | Oncology Today with Dr Neil Love: Role of PARP Inhibition in Ovarian Cancer (Companion Faculty Lecture) Dec 21, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Thomas Herzog, including the following topics:

Keys to evaluating genetics in patients with ovarian cancer (0:00)
Clinical trials evaluating PARP inhibitor maintenance therapy for patients with newly diagnosed ovarian cancer responding to platinum-based chemotherapy (7:35)
Current status of PARP inhibitor use in the care of patients with ovarian cancer (18:45)
Ongoing studies evaluating the combination of PARP and immune checkpoint inhibitors (24:37)

CME information and select publications

Ovarian Cancer | Oncology Today with Dr Neil Love: Role of PARP Inhibition in Ovarian Cancer Dec 21, 2022

Show notes

Featuring perspectives from Dr Thomas Herzog, including the following topics:

Impact of PARP inhibitors (PARPi) on the care of patients with ovarian cancer (0:00)
Clarifying the recent withdrawal of PARPi for treatment of recurrent or refractory ovarian cancer (4:13)
Sequential use of PARPi for patients with advanced ovarian cancer (16:56)
Case: Woman in her late 60s with BRCA wild type ovarian cancer (20:06)
Case: Woman in her early 50s with somatic BRCA-positive high-grade serous ovarian cancer (39:22)
Case: Woman in her mid 60s with BRCA wild type and homologous recombination-deficient endometroid ovarian cancer (44:02)

CME information and select publications

Non-Small Cell Lung Cancer | Alexander I Spira, MD, PhD Dec 16, 2022

Show notes

Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer — Faculty Presentation 2: TROP2 and Other Investigational Targets for ADCs in Advanced NSCLC — Dr Alexander Spira

CME information and select publications

Non-Small Cell Lung Cancer | Helena Yu, MD Dec 16, 2022

Show notes

Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer — Faculty Presentation 1: Targeting HER2 and HER3 with Antibody-Drug Conjugates (ADCs) in Non-Small Cell Lung Cancer (NSCLC) — Dr Helena Yu

CME information and select publications

Non‑Small Cell Lung Cancer | Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer Dec 16, 2022

Show notes

Featuring perspectives from Drs Alexander Spira and Helena Yu, including the following topics:

Introduction
- What is an antibody-drug conjugate? (0:00)
"HER2-Positive" Non-Small Cell Lung Cancer (NSCLC)
- Case: A woman in her mid 50s with HER2 insertion in exon 20 — Dr Yu (8:42)
Targeting HER3 in NSCLC
- Case: A man in his early 60s with lung cancer with an EGFR mutation — Dr Yu (25:23)
TROP2-Directed Treatment
- Case: A woman in her early 50s with lung cancer with a KRAS G12V mutation — Dr Spira (36:57)
- Case: A woman in her mid 60s with metastatic NSCLC and an EGFR exon 19 deletion — Dr Spira (39:32)
Novel Agents
- Mechanism of action of tusamitamab ravtansine and telisotuzumab vedotin (54:15)

CME information and select publications

Multiple Myeloma | BCMA-Directed Therapy in Multiple Myeloma: Expert Opinions and Patient Perspectives — Part 2 Dec 15, 2022

Show notes

Featuring perspectives from Dr S Vincent Rajkumar, including the following topics:

Introduction: Requiem for Belantamab Mafodotin? Dawn of a New Era (0:00)
Case: A man in his early 70s with multiregimen-refractory multiple myeloma (MM) receives idecabtagene vicleucel with Grade 1 cytokine release syndrome and persistent cytopenias — Jesús G Berdeja, MD (16:12)
Case: A man in his mid 60s with multiregimen-refractory MM receives idecabtagene vicleucel with a 20-month response — Dr Berdeja (25:19)
Case: A man in his late 50s with multiregimen-refractory MM received idecabtagene vicleucel in 2020 and is currently in complete remission — Natalie S Callander, MD (31:11)
Case: A man in his early 60s with multiregimen-refractory MM receives the novel bispecific antibody WVT078 on a clinical trial — Dr Callander (41:02)
Case: A man in his mid 70s with multiregimen-refractory MM receives teclistamab on a clinical trial — Dr Berdeja (51:21)

CME information and select publications

Melanoma | Oncology Today with Dr Neil Love: Novel Immunotherapeutic Strategies in Melanoma (Companion Faculty Lecture) Dec 13, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Omid Hamid, including the following topics:

Current evolution in the care of patients with metastatic melanoma (0:00)
Novel immunotherapeutic strategies for patients with untreated metastatic melanoma (1:47)
Efficacy and safety of novel agents and combination treatments for patients with previously treated metastatic melanoma (16:28)
Future directions in the care of patients with metastatic melanoma (25:13)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected